Vir Biotechnology, Inc. VIR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$125.7M-193% | -$42.92M+73.7% | -$163.14M-47.0% | -$110.96M+8.3% | -$120.97M-15.7% | ||
| $2.81M-3.0% | $2.9M-3.3% | $3M+2.8% | $2.92M+1.7% | $2.87M-0.7% | ||
| $12.09M+7.9% | $11.21M-1.3% | $11.36M-8.8% | $12.45M-11.4% | $14.06M-11.2% | ||
| -$4.23M-243% | $2.96M— | —— | $8.86M+726% | -$1.42M+26.9% | ||
| -$17.22M— | —— | -$14.16M+39.7% | -$23.47M-230% | $18.01M+137% | ||
| -$382K— | —— | -$4.22M-380% | -$879K+82.6% | -$5.06M— | ||
| -$2.27M+2.2% | -$2.32M-29.6% | -$1.79M-23.0% | -$1.46M+18.9% | -$1.8M+85.7% | ||
| -$132.39M-412% | -$25.88M+84.6% | -$167.57M-39.4% | -$120.22M-53.9% | -$78.12M+10.9% | ||
| $390K+12.1% | $348K+9.8% | $317K-87.5% | $2.54M+55.8% | $1.63M-18.3% | ||
| $158.37M-38.1% | $255.82M-3.3% | $264.45M+37.5% | $192.37M+10.8% | $173.69M+8.0% | ||
| $170.6M-50.3% | $342.93M+12.4% | $305.17M+21.4% | $251.32M-16.7% | $301.86M+0.2% | ||
| $11.84M-86.3% | $86.65M+114% | $40.45M-28.4% | $56.46M-55.5% | $126.82M-9.9% | ||
| $162.35M+16,234,800% | $1K-99.0% | $101K-91.9% | $1.25M— | $0-100% | ||
| $162.52M+15,542% | $1.04M+919% | $102K-95.0% | $2.05M+242% | $598K-52.7% | ||
| $41.97M— | —— | -$127.02M-106% | -$61.72M-225% | $49.3M-9.3% | ||
| -$394K+74.6% | -$1.55M-17.8% | -$1.32M+47.8% | -$2.52M+38.3% | -$4.09M-88.6% | ||
| $82K-37.9% | $132K— | —— | —— | $6K+100% | ||
| -$890K— | $0-100% | $560K-94.4% | $9.98M+869% | $1.03M-85.2% | ||
| -$17.22M— | —— | -$14.16M+39.7% | -$23.47M-230% | $18.01M+137% | ||
| -$2.27M+2.2% | -$2.32M-29.6% | -$1.79M-23.0% | -$1.46M+18.9% | -$1.8M+85.7% | ||
| -$657K-108% | $8.72M+212% | $2.79M-61.9% | $7.33M+218% | -$6.2M— | ||
| -$382K— | —— | -$4.22M-380% | -$879K+82.6% | -$5.06M— | ||
| $1.34M+1.0% | $1.33M+2.2% | $1.3M+4.9% | $1.24M+10.3% | $1.12M+2.0% | ||
| $170.6M-50.3% | $342.93M+12.4% | $305.17M+21.4% | $251.32M-16.7% | $301.86M+0.2% | ||
| $0— | —— | $37K-17.8% | $45K-84.0% | $281K-88.6% | ||
| $170K— | —— | -$1.34M— | —— | -$6.38M-645% | ||
| -$2.27M+2.2% | -$2.32M-29.6% | -$1.79M-23.0% | -$1.46M+18.9% | -$1.8M+85.7% | ||
| -$132.78M-406% | -$26.22M+84.4% | -$167.89M-36.8% | -$122.76M-53.9% | -$79.75M+11.0% | ||
| -$132.78M-406% | -$26.22M+84.4% | -$167.89M-36.8% | -$122.76M-53.9% | -$79.75M+11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vir Biotechnology, Inc. generate?
- Vir Biotechnology, Inc. (VIR) generated -$446.1M in operating cash flow over the trailing twelve months.
- What is Vir Biotechnology, Inc.'s free cash flow?
- After $3.6M of capital expenditures, Vir Biotechnology, Inc.'s free cash flow was -$449.6M over the trailing twelve months, down 6.5% year over year.
- Where does Vir Biotechnology, Inc.'s cash flow data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
